MSN set to launch molnupiravir generic drug for Covid-19 treatment
Hyderabad: MSN Group, a Hyderabad-based pharma company, is all set to launch the generic molnupiravir 200 mg capsules for treating Covid-19 under the brand name Moluflow.
Molnupiravir is an oral Covid-19 antiviral medicine indicated for the treatment of mild-to-moderate Covid-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness.
MSN Group said, “Being an orally administered option, we are confident that this medicine will increase treatment compliance and bring relief to the Covid-19 patients.”
Moluflow, which received Emergency Use Approval (EUA) approval from DCGI, comes as a pack of 4×10 capsule strips with each capsule in 200 mg strength. A dosing regimen of 800 mg (BID) for five days (four capsules of 200 mg twice a day) is recommended in addition to standard medical care.
Moluflow is being manufactured at MSN Group’s USFDA & MHRA accredited facility based out of Hyderabad. The drug, to be dispensed upon a medical prescription, will be made available at all retail pharmacies soon.
MSN Group, which has successfully conducted clinical trials of molnupiravir in India and presented its findings to DCGI, has recently received the licence from the Medicines Patent Pool (MPP) for manufacturing and distribution of MSD’s molnupiravir for treating Covid-19.
This agreement will also help MSN Group in enabling access to molnupiravir in over 100 low- and middle-income countries (LMICs) following regulatory approvals of respective countries.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
